GCP
SGMT icon

GSA Capital Partners’s Sagimet Biosciences SGMT Stock Holding History

GSA Capital Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,992
Closed -$73K – 2131
2026
Q1 		$73K Sell
13,992
-11,204
-44% -$62.4K ﹤0.01% 1587
2025
Q4 		$149K Sell
25,196
-60,052
-70% -$431K 0.01% 1479
2025
Q3 		$585K Buy
+85,248
New +$691K 0.05% 742
2025
Q2 		– Sell
-28,930
Closed -$94K – 2103
2025
Q1 		$94K Sell
28,930
-53,250
-65% -$223K 0.01% 1511
2024
Q4 		$370K Buy
+82,180
New +$416K 0.03% 1094
2024
Q2 		– Sell
-16,452
Closed -$89K – 1984
2024
Q1 		$89K Buy
+16,452
New +$118K 0.01% 1500

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

GSA Capital Partners's SGMT Position: Q2 2026 in Review

GSA Capital Partners sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 13,992 shares — an estimated $73K sold.

GSA Capital Partners first reported a position in SGMT in Q1 2024 and held it in 6 quarters. The position peaked at $585K in Q3 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • GSA Capital Partners reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 13,992 Sagimet Biosciences shares in Q2 2026, an estimated $73K.
  • GSA Capital Partners first reported a position in Sagimet Biosciences in Q1 2024 and held it in 6 quarters.
  • GSA Capital Partners's Sagimet Biosciences position peaked at $585K in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.